Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Gosuranemab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms TANGO
- Sponsors Biogen
- 17 Aug 2018 Planned End Date changed from 8 Sep 2021 to 9 Jul 2021.
- 17 Aug 2018 Planned primary completion date changed from 21 Jul 2021 to 9 Jul 2021.
- 26 Jul 2018 Trial design presented at the Alzheimer's Association International Conference 2018.